Opinion: A sloppy report on mifepristone is being used to undermine the FDA — and the biotech industry

For decades, the Food and Drug Administration has partnered with clinicians and industry to deliver evidence-based medical innovations using a gold-standard framework for drug development and oversight. The agency has the authority to review any approved drug, and such reviews are a vital part of ensuring public health. That process has long been grounded in transparent and methodologically sound science.

Now that approach is under threat. In April, the Ethics and Public Policy Center (EPPC), a conservative think tank, released a deeply flawed, politically driven report with the inflammatory title “The Abortion Pill Harms Women.” It’s being used to challenge the FDA’s long-standing approval of mifepristone, one of the FDA’s most studied medications. It’s been safely used by millions for more than two decades, with over 25 years of data confirming its safety and efficacy.

Read the rest…